Biomanufacturing Market Report: Supporting the bioboomAdd bookmark
The need for more speed to the market in biomanufacturing is fueling the acceptance and implementation of single use systems despite their complications
• Over 60% of respondents can see biomanufacturing sites becoming 100% disposable one day
• 59% of our base is aiming to have a fully disposable system.
• Over 60% seek new products from suppliers at least every 12 months.
The ways in which disposable systems simplify biomedicine production are persuading many to implement more of these devices into their production lines. Some have fully committed to this shift from stainless steel equipment, with the ambition to have fully disposable manufacturing lines one day.
The use of single-use bioprocessing equipment is making product manufacture increasingly efficient and frequently less costly, particularly for early stages of R&D. These devices are often the only viable options for smaller and lesser-funded companies that wish to manufacture candidates in-house.
Support for the bioboom
With the demand for biopharma predicted to hold its ascent, industry players are forced to optimize biomanufacturing strategies. By 2021, the biosimilars market is predicted to be more than double the size it was in 2016.
The rise of personalized medicines has led to the focus on small scale manufacture with a key challenge being that lots of the same element need to process through a facility simultaneously. For this reason, randomized trials with complex gene therapies can encounter manufacturing hurdles.
In discovering new biomedicines, to meet required standards for clinical results, producers need reliable manufacturing processes and technologies that have a high degree of quality built into them. This can be hard to achieve with some manufacturing platforms imposing limitations on scale and cell density, especially regarding commercial scale.
There is a marked need for integrated manufacturing platforms. Existing solutions for the different steps in the manufacturing process are not always interoperable from a product flow or an analytics perspective. Success may be found in reaching standardized platforms that are connectable – which is not an easy task.
With the importance of biomanufacturing only set to grow, Pharma IQ examines the trends occurring within disposable systems which will have a key part to play in realizing the advanced stages of the bioboom.